Erkure Therapeutics
is raising ₹10.0L Pre seed via SAFE / iSAFE
Elevator pitch
“Glucose-targeted liposomal nanoparticles that collapse tumour energy metabolism, logic-gated so healthy tissue is spared. Pre-clinical oncology from India. First in-vitro proof in 90 days.”
About
We build glucose-targeted nanoparticles that collapse tumour energy metabolism, logic-gated so healthy tissue is spared. Pre-clinical oncology, first in-vitro proof in 90 days.
Use of funds
20% scientist fee for the in-vitro programme. 9% bench access in Delhi NCR. 11% consumables: kits, mini-extruder, lipids and dialysis. 6.5% cell line, plates, dye and analytical readouts. 8% founder living support through the 90-day execution window. 10% contingency, including company incorporation. 30% held for the repeat round and a second cell line once first data lands.